Disruption of CDK4/6-RB pathway and an uncontrolled G1 to S transition is a common feature of cancer cells (Hamilton and Infante, 2016). Therefore, CDK4/6 have long been regarded as promising targets for cancer therapies. This evidence concerns the gene CDK4 and cancer.